Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Priority Reports

Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells

Maria Y. Wang, Kan V. Lu, Shaojun Zhu, Ederlyn Q. Dia, Igor Vivanco, Gregory M. Shackleford, Webster K. Cavenee, Ingo K. Mellinghoff, Timothy F. Cloughesy, Charles L. Sawyers and Paul S. Mischel
Maria Y. Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kan V. Lu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaojun Zhu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ederlyn Q. Dia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igor Vivanco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M. Shackleford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Webster K. Cavenee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingo K. Mellinghoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy F. Cloughesy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles L. Sawyers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul S. Mischel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-04-4392 Published August 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    PTEN, EGFR, and EGFRvIII interaction regulates PI3K pathway activation and tumor cell proliferation. A, schematic diagram showing the retroviral transduction strategy for generating U87 glioblastoma cells expressing EGFR, EGFRvIII, and PTEN in all relevant combinations. B, stimulation of serum-starved cells with 10 ng/mL EGF for 15 minutes induced EGFR phosphorylation and resulted in downstream phosphorylation of Akt and Erk kinases. The ligand-independent mutant EGFRvIII was constitutively phosphorylated and increased baseline Akt and Erk phosphorylation compared with parental U87MG cells, whereas PTEN consistently diminished basal Akt activation, but not Erk, in unstimulated cells. C, cell proliferation under serum-free conditions over 5 days was dramatically increased in EGFRvIII-expressing cells compared with parental U87MG cells, whereas PTEN effectively inhibited EGFRvIII-mediated proliferation, as well as proliferation of U87MG cells.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    EGFRvIII and PTEN coexpression sensitizes glioblastoma cells to erlotinib. Treatment with 10 μmol/L erlotinib for 48 hours substantially increased the G1 fraction of U87-PTEN-EGFRvIII cells relative to U87-EGFRvIII cells, and of U87-PTEN cells relative to U87MG cells. Experiments were repeated thrice and representative results from one experiment are presented.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Rapamycin enhances glioblastoma sensitivity to erlotinib, particularly in PTEN-deficient cells. A, cells were treated with 10 μmol/L erlotinib, 1 nmol/L rapamycin, or a combination of both inhibitors in serum-containing whole medium for 2 days. Erlotinib monotherapy diminished phosphorylation of both EGFR and EGFRvIII, but S6 phosphorylation was reduced only when PTEN was coexpressed in U87-PTEN and U87-PTEN-EGFRvIII cells. The presence of rapamycin in combination with erlotinib completely inhibited S6 phosphorylation, even in cells lacking PTEN. B, dose response of glioblastoma cell lines to erlotinib, rapamycin, or a combination of erlotinib and 0.1 nmol/L rapamycin over 10 to 14 days was determined in 96-well drug sensitivity assays. Concurrent administration of 0.1 nmol/L rapamycin alongside a range of erlotinib doses showed an additive effect and lowered the erlotinib IC50 in all cell lines, with considerably more decrease in PTEN-deficient cell lines (U87, U87-EGFR, and U87-EGFRvIII). This indicated that rapamycin could sensitize PTEN-deficient cells to erlotinib. The additive effect was less pronounced in U87-PTEN-EGFRvIII cells, which are already highly sensitive to erlotinib. C, the fold reduction in erlotinib IC50 value resulting from the addition of rapamycin is shown for each cell line. Combining rapamycin with erlotinib had a significantly greater erlotinib IC50-reducing effect on PTEN-deficient glioblastoma cells in each of the three matched pairs (P = 0.00001).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Combined erlotinib and rapamycin treatment induces growth arrest and cell death in PTEN-deficient SF295 glioblastoma cells. A, SF295 cells stably expressing PTEN exhibit reduced baseline levels of Akt phosphorylation. B, cells were treated with 10 μmol/L erlotinib, 1 nmol/L rapamycin, or a combination of both inhibitors in serum-free medium for 2 days before being stimulated with 10 ng/mL EGF for 15 minutes. Erlotinib (10 μmol/L) strongly inhibited Akt phosphorylation and slightly reduced S6 phosphorylation in both cell lines, whereas 1 nmol/L rapamycin only diminished S6 activation. In contrast, combined erlotinib and rapamycin treatment effectively inhibited both Akt and S6 phosphorylation. C, SF295-PTEN cells were significantly more sensitive to erlotinib-mediated cell death than SF295 cells after 3 to 4 days treatment. However, the addition of rapamycin to erlotinib sensitized PTEN-deficient SF295 cells, matching the drug-induced cell death observed in erlotinib-treated SF295-PTEN cells. Combined erlotinib and rapamycin treatment also provided significant additional benefit to SF295-PTEN cells. D, the population of cells in G1 phase was dramatically higher when treated with both erlotinib and rapamycin compared with treatment with either drug alone for 48 hours.

Additional Files

  • Figures
  • Supplementary Data Wang, et al.

    Files in this Data Supplement:

    • Supplementary Table 1
PreviousNext
Back to top
Cancer Research: 66 (16)
August 2006
Volume 66, Issue 16
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells
Maria Y. Wang, Kan V. Lu, Shaojun Zhu, Ederlyn Q. Dia, Igor Vivanco, Gregory M. Shackleford, Webster K. Cavenee, Ingo K. Mellinghoff, Timothy F. Cloughesy, Charles L. Sawyers and Paul S. Mischel
Cancer Res August 15 2006 (66) (16) 7864-7869; DOI: 10.1158/0008-5472.CAN-04-4392

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells
Maria Y. Wang, Kan V. Lu, Shaojun Zhu, Ederlyn Q. Dia, Igor Vivanco, Gregory M. Shackleford, Webster K. Cavenee, Ingo K. Mellinghoff, Timothy F. Cloughesy, Charles L. Sawyers and Paul S. Mischel
Cancer Res August 15 2006 (66) (16) 7864-7869; DOI: 10.1158/0008-5472.CAN-04-4392
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • ATM Loss and Therapeutic Sensitivities in Prostate Cancer
  • Multimodal Molecular Imaging of the Tumor Microenvironment
  • Linear Evolutionary Model of Breast Cancer
Show more Priority Reports
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement